| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NTM |
| Uniprot No | Q9P121-3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-312aa |
| 氨基酸序列 | MGVCGYLFLP WKCLVVVSLR LLFLVPTGVP VRSGDATFPK AMDNVTVRQG ESATLRCTID NRVTRVAWLN RSTILYAGND KWCLDPRVVL LSNTQTQYSI EIQNVDVYDE GPYTCSVQTD NHPKTSRVHL IVQVSPKIVE ISSDISINEG NNISLTCIAT GRPEPTVTWR HISPKAVGFV SEDEYLEIQG ITREQSGDYE CSASNDVAAP VVRRVKVTVN YPPYISEAKG TGVPVGQKGT LQCEASAVPS AEFQWYKDDK RLIEGKKGVK VENRPFLSKL IFFNVSEHDY GNYTCVASNK LGHTNASIML FG |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NTM(非结核分枝杆菌)重组蛋白研究的虚构参考文献示例(实际文献需通过学术数据库查询)：
1. **文献名称**: *Heterologous expression and immunogenicity analysis of NTM membrane proteins*
**作者**: Smith, J.R., et al.
**摘要**: 本研究成功在大肠杆菌中克隆表达了NTM菌株的两种膜蛋白(Rv1234和Rv5678)，通过动物实验证明重组蛋白可诱导特异性Th1免疫反应，为NTM亚单位疫苗开发提供候选抗原。
2. **文献名称**: *Recombinant NTM antigens for serodiagnosis of pulmonary infections*
**作者**: Li, X., & Wang, H.
**摘要**: 筛选NTM基因组中3种分泌蛋白(ESAT-6、CFP-10、Ag85B)进行重组表达，ELISA检测显示联合使用可提升临床样本诊断特异性至92%，为NTM感染血清学检测提供新方案。
3. **文献名称**: *Structural and functional characterization of a novel NTM virulence factor*
**作者**: Gonzalez, S., et al.
**摘要**: 通过X射线晶体学解析NTM重组蛋白MmpL3的3D结构(分辨率2.1Å)，发现其转运脂质的关键结构域，抑制剂筛选实验证实该蛋白可作为抗菌药物开发靶点。
4. **文献名称**: *Comparative proteomic analysis of recombinant NTM stress-response proteins*
**作者**: Tanaka, K., et al.
**摘要**: 系统表达并纯化NTM热休克蛋白家族(Hsp16-20、Hsp65、Hsp70)，通过蛋白质相互作用组学揭示其在细菌环境适应中的调控网络，为理解NTM耐药机制提供分子依据。
(注：上述文献为示例性质，实际研究需参考PubMed、Web of Science等平台的真实论文)
**Background of Recombinant Proteins in Nontuberculous Mycobacteria (NTM) Research**
Nontuberculous mycobacteria (NTM) are environmentally ubiquitous, opportunistic pathogens increasingly associated with chronic pulmonary infections, particularly in immunocompromised individuals or those with pre-existing lung conditions. Unlike *Mycobacterium tuberculosis*, NTM species (e.g., *M. avium*, *M. abscessus*) exhibit broad genetic diversity and intrinsic resistance to many antibiotics, complicating treatment. Traditional drug development faces challenges due to NTM’s slow growth, complex lipid-rich cell walls, and biofilm-forming capabilities.
Recombinant protein technology has emerged as a critical tool to address these hurdles. By cloning and expressing NTM-specific genes in heterologous systems (e.g., *E. coli*, yeast), researchers produce purified proteins to study virulence factors, host-pathogen interactions, and immune responses. For instance, recombinant antigens like Apa (alanine-proline-rich antigen) and Ag85 complex proteins have been leveraged to develop diagnostic assays and vaccine candidates. These proteins enable serological tests to differentiate NTM infections from tuberculosis, addressing a key clinical challenge.
Moreover, recombinant approaches facilitate targeted drug discovery. Enzymes involved in NTM’s unique metabolic pathways (e.g., mycobactin synthesis) or resistance mechanisms (e.g., macrolide-modifying enzymes) are expressed and purified for high-throughput inhibitor screening. Additionally, recombinant proteins aid in deciphering immune evasion strategies, such as modulation of cytokine signaling, informing immunotherapeutic strategies.
The scalability and cost-effectiveness of recombinant protein production also support rapid prototyping of subunit vaccines and monoclonal antibodies. As antibiotic resistance escalates, these strategies offer promising alternatives to conventional therapies. Continued advances in bioinformatics and structural biology further enhance the design of recombinant proteins, accelerating translational research against NTM infections.
In summary, recombinant protein technology underpins efforts to overcome NTM’s clinical and biological complexities, bridging gaps in diagnostics, therapeutics, and mechanistic understanding.
×
